The working hypothesis of our laboratory remains there is a convergence of prosurvival, angiogenesis and motility signals at common pathways in the local tumor microenvironment and thus these events can be efficiently targeted therapeutically. We have focused to two pathways identified in our previous studies: function of the BAG-3 stress co-chaperone protein, identified in our CAI studies, and progranulin (GEP), a growth and invasion factor for ovarian cancer, identified in our analysis of cDNA libraries from microdissected clinical ovarian cancer samples. We continue our studies of the protective effects of BAG-3 on cell stress in dissection of its sensitivity to staurosporine treatment. We have identified and are further characterizing two mechanisms of regulation of BAG-3 protein stability and therefore survival support functions. Ongoing work also is dissecting the phenotype of transfectants of wild type and deletion mutants of BAG-3 in adhesion, motility, and cytoskeletal reorganization. We have identified alterations in the activation status of the src>fak and src>cas pathways. Analysis is ongoing also on the changes in gene expression in these mutants. Findings are consistent with the observed reduction in xenograft aggressiveness with the deletion mutants. Lastly, clinical correlative studies using immunohistochemistry are ongoing to assess the relationship of expression in epithelial ovarian of BAGs 1, 3, and 4. Studies of the Drosophila homolog of BAG 3/4, evil, continue and transgenic flies are being characterized currently for phenotype. Contract yeast 2-hybrid and siRNA production are nearing completion and validation studies have begun. Our work in ovarian cancer identified GEP as a growth and survival factor. Current results indicate that GEP production is regulated by pathways activated by G protein-coupled growth factors known to be active in ovarian cancer, LPA and endothelin through a cAMP/EPAC/MAPK pathway. Downregulation of GEP with neutralizing antibodies causes apoptosis of ovarian cancer cells. We have further demonstrated that secretory leukocyte protease inhibitory factor, SLPI, is a partner protein of GEP and also necessary for survival of ovarian cancer cells in culture. Xenograft and mutation studies have commenced. Production of GEP and its subsequent activity may be part of a signal amplification cascade in ovarian cancer and is a logical target for molecular therapeutics. Clinical assessment showed a link between GEP expression in ovarian cancer malignant effusions and patient outcome. Thus, GEP and BAG-3 each have potential as molecular therapeutic targets in ovarian cancer and other solid tumors.

Agency
National Institute of Health (NIH)
Type
Intramural Research (Z01)
Project #
1Z01SC009163-18
Application #
7292046
Study Section
(LP)
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
2005
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Rasool, Nabila; LaRochelle, William; Zhong, Haihong et al. (2010) Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells. Clin Cancer Res 16:600-9
Devoogdt, Nick; Rasool, Nabila; Hoskins, Ebony et al. (2009) Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. Cancer Sci 100:434-40
Gunn, Andrew J; Hama, Yukihiro; Koyama, Yoshinori et al. (2007) Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Cancer Sci 98:1727-33
Davidson, Ben; Espina, Virginia; Steinberg, Seth M et al. (2006) Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 12:791-9
Kassis, Jareer N; Guancial, Elizabeth A; Doong, Howard et al. (2006) CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins. Exp Cell Res 312:2962-71
Kassis, Jareer; Klominek, Julius; Kohn, Elise C (2005) Tumor microenvironment: what can effusions teach us? Diagn Cytopathol 33:316-9
Kamrava, Mitchell; Simpkins, Fiona; Alejandro, Emilyn et al. (2005) Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene 24:7084-93
Perabo, Frank G E; Demant, Andre W; Wirger, Andreas et al. (2005) Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model. Anticancer Res 25:725-9
Winters, Mary E; Mehta, Arpita I; Petricoin 3rd, Emanuel F et al. (2005) Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. Cancer Res 65:3853-60
Davidson, Ben; Alejandro, Emilyn; Florenes, Vivi Ann et al. (2004) Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 100:2139-47

Showing the most recent 10 out of 20 publications